Our Deals
Deals
Gentiae Raised $16M in Series B Preferred Shares from Bay City Capital and CIBC January 3, 2007
Overview
On January 3, 2007, Gentiae Clinical Research Inc., which focuses on cardiac assessment services for clinical trials, closed a $16 million funding round, led by San Francisco-based Bay City Capital.
Funding was also provided by new investors, Toronto, Canada-based CIBC Capital Partners and London, U.K.-based Merlin Biomed Group; as well as by existing investor, Portola Valley-based Three Arch Partners.
Significance
In connection with the funding, Bay City Capital’s William G. Gerber, M.D. will join the board of directors.
Crosstree’s Role
Crosstree Capital Partners was the exclusive financial advisor for Gentiae Clinical Research.
Sub-Sector
Pharma Services
Healthcare Technology
Type
Recapitalization / Restructuring
Deal Tags
Pharma Lab Services
Clinical Site Transactions
Clinical Trials
Pharma Development
CRO